Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 44,980 shares at $81.15 ($3.7M) on 2026-08-18, disclosed to the SEC on 2026-08-20.
Scheduled sale ($3.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.15 | 1,900 | $154K | 4.1% |
| 2 | $82.21 | 17,279 | $1.4M | 38.1% |
| 3 | $82.99 | 14,602 | $1.2M | 32.5% |
| 4 | $83.77 | 1,199 | $100K | 2.7% |
| 5 | $83.86 | 8,100 | $679K | 18.2% |
| 6 | $84.69 | 1,800 |
| $152K |
| 4.1% |
| 7 | $85.65 | 100 | $9K | 0.2% |
| Total | $82.86 avg | 44,980 | $3.7M | 100% |
| Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |
| BBIO | SELL | 2026-04-13 | $6.0M | — | Filing → |